Novartis | Операционный Доход



Operating Profit Изменить Дата
AbbVie USD -1490000000 5.32B 2024-12
Alcon AG USD 395M 63M 2024-12
Almirall EUR 53.03M 68.53M 2024-06
Amgen USD 2.31B 182M 2024-12
AstraZeneca USD 2.04B 731M 2024-12
Autolus Therapeutics Ltd -67876000 8.95M 2024-09
Bayer EUR 3.53B 7.35B 2024-12
Biogen USD 441.4M 24.4M 2024-12
Bristol-Myers Squibb USD 793M 1.39B 2024-12
Eli Lilly USD 5.15B 3.62B 2024-12
Fresenius EUR 469M 23M 2024-12
Fresenius Medical Care EUR 258.9M 204.1M 2024-12
Galapagos EUR -62720000 8.41M 2024-12
Genmab DKK 2.19B 89M 2024-12
Gilead Sciences USD 2.45B 1.56B 2024-12
GlaxoSmithKline GBP 696M 507M 2024-12
GRIFOLS EUR 371.86M 54.83M 2024-12
Hikma Pharmaceutical USD 327M 208M 2024-06
J&J USD 3.89B 549M 2024-12
Lonza CHF 534M 194M 2024-06
Merck EUR 1.1B 305M 2024-09
Merck USD 4.3B 369M 2024-12
Novartis USD 2.28B 1.34B 2024-12
Novartis USD 3.4B 193M 2024-12
Novo Nordisk 33.82B 7.89B 2024-09
Orion EUR 92.7M 109.3M 2024-12
Pfizer USD -409000000 5.57B 2024-12
Philips EUR 199M 139M 2024-12
Recordati EUR 162.68M 13.82M 2024-09
Regeneron Pharmaceuticals USD 990.2M 189.3M 2024-12
Roche Holding CHF 4.39B 1.04B 2024-12
Sanofi EUR 4.09B 1.81B 2024-09
UCB EUR 163M 39M 2024-06



Novartis Операционный Доход - Текущие значения, предыдущие значения, прогнозы, графики и экономический календарь - Mar 2025.